Cardiovascular effects of the somatostatin analog octreotide in acromegaly.

No abstract is available for this paper.

• Publication year

  1990

• Venue

  Annals of Internal Medicine

• Publication date

  1990-12-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.7326/0003-4819-113-12-921PMID 2240917
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A hyperkinetic heart in uncomplicated active acromegaly. Explanation of hypertension in acromegalic patients?

  2009cited by this paper
• Atrial natriuretic factor in patients with acromegaly

  2006cited by this paper
• THE CARDIOVASCULAR EFFECTS OF OCTREOTIDE TREATMENT IN ACROMEGALY: AN ECHOCARDIOGRAPHIC STUDY

  1989cited by this paper
• Heart failure responding to octreotide in patient with acromegaly.

  1989cited by this paper
• Effects of Long-Term Administration of Sandostatin® (SMS 201–995) at Increasing Doses in 40 Acromegalic Patients. Results from the French Sandostatin Acromegaly Study Group

  1988cited by this paper
• The effect of subcutaneous infusion versus subcutaneous injections of a somatostatin analogue (SMS 201-995) on the diurnal GH profile in acromegaly.

  1987cited by this paper
• [Cardiovascular involvement in acromegaly. Apropos of 3 cases].

  1987cited by this paper
• Acromegalic heart disease: influence of treatment of the acromegaly on the heart.

  1987cited by this paper
• Impaired left ventricular diastolic function in acromegaly: an echocardiographic study.

  1987cited by this paper
• ACROMEGALY

  1987cited by this paper
• Rapid improvement in sleep apnoea of acromegaly after short-term treatment with somatostatin analogue SMS 201-995.

  1986cited by this paper
• [Cardiac insufficiency in acromegaly. Apropos of a case].

  1985cited by this paper
• Long-term treatment of acromegaly with the somatostatin analogue SMS 201-995.

  1985cited by this paper
• Myocardial involvement in acromegaly.

  1984cited by this paper
• Bromocriptine for an acromegalic patient. Improvement in cardiac function and carpal tunnel syndrome.

  1980cited by this paper
• Pathology of the heart in acromegaly: anatomic findings in 27 autopsied patients.

  1980cited by this paper
• Echocardiographic assessment of cardiac anatomy and function in acromegalic patients.

  1979cited by this paper
• Acromegaly and the heart. An echocardiographic study.

  1979cited by this paper
• Heart size and function in acromegaly.

  1979cited by this paper
• Cardiac Size and Function in Acromegaly

  1977cited by this paper
• Dysrhythmias and sudden death in acromegalic heart disease. A clinicopathologic study.

  1977cited by this paper
• Acromegaly and cardiovascular disorders. A prospective study.

  1974cited by this paper
• Cardiac function in acromegaly. A clinical and hemodynamic study.

  1974cited by this paper
• [The heart in acromegaly. Haemodynamic study].

  1973cited by this paper
• Heart muscle disease in acromegaly.

  1970cited by this paper
• Cardiac Function in Acromegaly

  1969cited by this paper
• Acromegaly and Gigantism

  1950cited by this paper

• Cardiomyopathy in patients with acromegaly - not truly a concern anymore?

  2025cites this paper
• Acromegalic Cardiomyopathy: An Entity on its own? The Effects of GH and IGF-I Excess and Treatment on Cardiovascular Risk Factors.

  2023cites this paper
• Acromegaly

  2022cites this paper
• Chemical phenotypes of intrinsic cardiac neurons in the newborn pig (Sus scrofa domesticus Erxleben, 1777)

  2021cites this paper
• Pegvisomant and not somatostatin receptor ligands (SRLs) is first line medical therapy for acromegaly.

  2020cites this paper
• Hypertension in Acromegaly

  2020cites this paper
• Secondary Hypertension

  2020cites this paper
• Cardiovascular complications of acromegaly.

  2020cites this paper
• Effects of somatostatin analog treatment on cardiovascular parameters in patients with acromegaly: A systematic review

  2019cites this paper
• Octreotide-induced sinus bradycardia in a male patient with acromegaly

  2019cites this paper
• Complete Heart Block due to Octreotide Infusion in Patient with Cryptogenic Cirrhosis.

  2019cites this paper
• ECHOCARDIOGRAPHIC MYOCARDIAL CHANGES IN ACROMEGALY: A CROSS-SECTIONAL ANALYSIS IN A TERTIARY CENTER IN BULGARIA.

  2019cites this paper
• A Novel Somatostatin-Dopamine Chimera (BIM23B065) Reduced GH Secretion in a First-in-Human Clinical Trial

  2018cites this paper
• Current Diagnostic and Treatment Strategies for Specific Dilated Cardiomyopathies: A Scientific Statement From the American Heart Association.

  2016cites this paper
• Acromegaly and the Vascular System

  2015cites this paper
• Cardiovascular Disease and Sleep-Disordered Breathing in Acromegaly

  2015cites this paper
• Acromegaly.

  2014cites this paper
• Growth hormone, insulin-like growth factor-1, and the kidney: pathophysiological and clinical implications.

  2014cites this paper
• A comprehensive study of clinical, biochemical, radiological, vascular, cardiac, and sleep parameters in an unselected cohort of patients with acromegaly undergoing presurgical somatostatin receptor ligand therapy.

  2013cites this paper
• [Octreotide-induced sinus bradycardia in a male patient with acromegaly].

  2013cites this paper
• Cardiovascular involvement in patients affected by acromegaly: an appraisal.

  2013cites this paper
• Octreotide-induced sinus bradycardia in a male patient with acromegaly

  2013cites this paper
• Bradicardia sinusal inducida por octreotide en un varón con acromegalia

  2013cites this paper
• Pathophysiology of renal calcium handling in acromegaly: what lies behind hypercalciuria?

  2012cites this paper
• OR01-3 Pathophysiology of renal calcium handling in acromegaly: What lies behind hypercalciuria?

  2012cites this paper
• Octreotide Long-Acting Release (LAR)

  2012cites this paper
• CLINICAL EXPERIENCE AND OUTCOME OF PITUITARY SURGERY IN KENYAN PATIENTS AT THE KENYATTA NATIONAL HOSPITAL EXPÉRIENCE ET RÉSULTATS DE LA CHIRURGIE HYPOPHYSAIRE CHEZ DES PATIENTS KENYANS AU KENYATTA NATIONAL HOSPITAL

  2012cites this paper
• Growth Hormone and the Cardiovascular System

  2012cites this paper
• Body fluid expansion in acromegaly is related to enhanced epithelial sodium channel (ENaC) activity.

  2011cites this paper
• Chapter 14 – Acromegaly

  2011cites this paper
• Acromegalia y enfermedad cardiovascular

  2011cites this paper
• A case of complete heart block induced by octreotide.

  2010cites this paper
• Acromegaly pathogenesis and treatment.

  2009cites this paper
• Diastolic Function Study with Conventional and Pulsed Tissue Doppler Echocardiography Imaging in Acromegalic Patients

  2009cites this paper
• Diagnostic challenges in acromegaly: a case-based review.

  2009cites this paper
• Pituitary tumours: acromegaly.

  2009cites this paper
• The GH/IGF-1 Axis and Heart Failure

  2009cites this paper
• Acromegaly

  2008cites this paper
• Octreotide-LAR vs lanreotide-SR as first-line therapy for acromegaly: A retrospective, comparative, head- to- head study

  2008cites this paper
• GH and IGF‐I excess control contributes to blood pressure control: results of an observational, retrospective, multicentre study in 105 hypertensive acromegalic patients on hypertensive treatment

  2008cites this paper
• Epithelial sodium channel is a key mediator of growth hormone-induced sodium retention in acromegaly.

  2008cites this paper
• Assessment of the awareness and management of cardiovascular complications of acromegaly in Italy. The COM.E.T.A. (COMorbidities Evaluation and Treatment in Acromegaly) Study

  2008cites this paper
• Resolution of acromegalic cardiomyopathy in mild acromegalic physical abnormality after short-term octreotide therapy

  2007cites this paper
• Acromegaly improved with sandostatin LAR treatment

  2007cites this paper
• The long-term cardiovascular outcome of different GH-lowering treatments in acromegaly

  2007cites this paper
• Cardiovascular effects of octreotide, a long-acting somatostatin analog

  2006cites this paper
• Histopathological Improvement Cardiomyopathy by Intermittent Infusion of Octreotide # of Acromegalic Subcutaneous

  2006cites this paper
• Gene expression profile in the heart of spontaneous dwarf rat: in vivo effects of growth hormone.

  2006cites this paper
• A Case and Review of Acromegaly-Induced Cardiomyopathy and the Relationship Between Growth Hormone and Heart Failure: Cause or Cure or Neither or Both?

  2006cites this paper
• [Cardiac morphology and performance alterations and analysis of determinant factors of left ventricular hypertrophy in 40 patients with acromegaly].

  2006cites this paper
• atualização Etiologic Aspects and Management of Acromegaly

  2005cites this paper
• Etiologic aspects and management of acromegaly.

  2005cites this paper
• Growth hormone and fluid homeostasis.

  2005cites this paper
• Somatostatin receptor subtype expression in the human heart: differential expression by myocytes and fibroblasts.

  2005cites this paper
• PREVALÊNCIA DA APNÉIA DO SONO EM PACIENTES COM ACROMEGALIA E ANÁLISE DOS PARÂMETROS CEFALOMÉTRICOS À RESSONÂNCIA MAGNÉTICA

  2005cites this paper
• [Acromegaly in elderly people].

  2005cites this paper
• Acromégalie du sujet âgé

  2005cites this paper
• The role of somatostatin receptors in the medical treatment of acromegaly.

  2004cites this paper
• Octreotide-induced bradycardia and heart block during surgical resection of a carcinoid tumor.

  2004cites this paper
• The effects of octreotide in dilated cardiomyopathy: an open-label trial in 12 patients.

  2004cites this paper
• Long-term outcome of patients with acromegaly and congestive heart failure.

  2004influential citation
• When head rules heart.

  2004cites this paper
• Systemic complications of acromegaly: epidemiology, pathogenesis, and management.

  2004cites this paper
• Cardiac Abnormalities in Acromegaly

  2004cites this paper
• Somatostatin Analogs in the Treatment of Pituitary Tumors

  2004cites this paper
• Clinical pharmacological aspects of growth hormone administration.

  2004cites this paper
• THE EFFECT OF GROWTH HORMONE ON IDIOPATHIC DILATED CARDIOMYOPATHY

  2003cites this paper
• Early Diagnosis and Treatment of Endocrine Disorders

  2003cites this paper
• Improvement of ventricular arrhythmia by octreotide treatment in acromegalic cardiomyopathy.

  2003cites this paper
• Effects of growth hormone on fluid homeostasis. Clinical and experimental aspects.

  2003cites this paper
• Comparison of efficacy and tolerability of somatostatin analogs and other therapies for acromegaly

  2003cites this paper
• High output heart failure in patients with newly diagnosed acromegaly.

  2002cites this paper
• Effect of a six-month treatment with lanreotide on cardiovascular risk factors and arterial intima-media thickness in patients with acromegaly.

  2002cites this paper
• Pituitary Disease

  2002cites this paper
• Improvement of cardiac function after treatment with octreotide followed by trans-sphenoidal surgery in an acromegalic patient who presented with congestive heart failure.

  2002cites this paper
• Marked improvement in cardiovascular function after successful transsphenoidal surgery in acromegalic patients

  2001influential citation
• Alteración de la función diastólica de ambos ventrículos en la acromegalia

  2001cites this paper
• Acromegaly: historical perspectives and current therapy

  2001cites this paper
• Growth hormone and the heart

  2001cites this paper
• Increased arterial intima‐media thickness by B‐M mode echodoppler ultrasonography in acromegaly

  2001cites this paper
• [Biventricular impairment of diastolic function in acromegaly].

  2001cites this paper
• Impact of Growth Hormone-Lowering Treatments on Heart Function in Acromegaly

  2001cites this paper
• Surgical Treatment and Clinical Outcome of GH-Secreting Adenomas in Elderly Patients

  2001cites this paper
• Physiological Effects of Growth Hormone on the Heart

  2001cites this paper
• Is the acromegalic cardiomyopathy reversible? Effect of 5-year normalization of growth hormone and insulin-like growth factor I levels on cardiac performance.

  2001cites this paper
• TREATMENTS ON HEART FUNCTION IN ACROMEGALY

  2001cites this paper
• Cardiovascular effects of growth hormone

  2000cites this paper
• Vascular reactivity in acromegalic patients: preliminary evidence for regional endothelial dysfunction and increased sympathetic vasoconstriction

  2000influential citation
• New Medical Approaches in Pituitary Adenomas

  2000cites this paper
• Advances in the Treatment of Congestive Heart Failure: New Approaches for an Old Disease

  2000cites this paper
• Baseline and stimulated catecholamine secretion in normotensive patients with active acromegaly: acute effects of continuous octreotide infusion.

  2000cites this paper
• Growth hormone and cardiac function.

  2000cites this paper
• Treatment with growth hormone enhances contractile reserve and intracellular calcium transients in myocytes from rats with postinfarction heart failure.

  1999cites this paper
• Regression of acromegalic left ventricular hypertrophy after lanreotide (a slow-release somatostatin analog).

  1999cites this paper
• Effects of a 7-day continuous infusion of octreotide on circulating levels of growth factors and binding proteins in growth hormone (GH)-treated GH-deficient patients.

  1999cites this paper
• Local insulin‐like growth factor I expression induces physiologic, then pathologic, cardiac hypertrophy in transgenic mice

  1999cites this paper
• Impact of patient's age and disease duration on cardiac performance in acromegaly: a radionuclide angiography study.

  1999cites this paper
• Markers of ventricular tachyarrythmias in patients with acromegaly.

  1999cites this paper
• Cardiac effects of slow-release lanreotide, a slow-release somatostatin analog, in acromegalic patients.

  1999cites this paper
• Effects of 1-year treatment with octreotide on cardiac performance in patients with acromegaly.

  1999cites this paper